Analysis of US Patent 9,125,905: Scope, Claims, and Patent Landscape
What does US Patent 9,125,905 cover?
US Patent 9,125,905, issued on September 1, 2015, by the United States Patent and Trademark Office (USPTO), pertains to a crystalline form of a pharmaceutical compound used primarily in the treatment of AIDS/HIV. The patent discloses a specific crystalline salt form of a drug candidate and covers its preparation, composition, and therapeutic application.
Key details:
- Title: Crystalline form of a HIV-1 integrase inhibitor
- Assignee: Gilead Sciences, Inc.
- Application filing date: March 29, 2013
- Issue date: September 1, 2015
- Related patents: Several continuation and divisional applications build on this patent.
What are the primary claims?
The patent includes 17 claims, with the core assertions focusing on the crystalline salt form, its preparation, and pharmaceutical compositions.
Main Claims Breakdown
Claim 1: Defines a crystalline salt of a specific HIV integrase inhibitor, characterized by X-ray powder diffraction (XRPD) patterns. It includes a salt form with specific structural features and stereochemistry.
Claims 2-5: Address the preparation methods of the crystalline salt, including processes involving specific solvents and conditions.
Claims 6-8: Cover pharmaceutical compositions, including formulations that contain the crystalline salt for therapeutic use.
Claims 9-17: Address methods of synthesizing the crystalline forms, their stability, and use in treatment, emphasizing improved bioavailability and stability of the crystalline salt.
Note: The claims emphasize the crystalline nature, specific XRPD patterns, and methods of preparation to establish patent scope and exclusivity.
How broad is the patent scope?
The patent claims are structured to encompass:
- Specific crystalline salt forms identified by XRPD patterns
- Processes to produce these crystalline forms
- Pharmaceutical compositions containing these forms
- Uses of the crystalline salt in treating HIV/AIDS
Scope analysis:
- The claims focus on the crystalline salt with defined analytical features (XRPD peaks)
- They specify synthesis methods, ensuring control over the crystalline form
- The composition claims broaden protection to include formulations used in therapy
- The inclusion of method claims enhances control over production processes
Limitations:
- The scope is limited to the crystalline salt with the described XRPD pattern. Variations outside these specific patterns may not infringe
- The process claims are limited to certain solvents and conditions, offering opportunities for alternative methods outside the scope
Patent landscape overview
Similar patents and related applications
Gilead has a broad portfolio covering HIV integrase inhibitors and crystalline forms:
- US Patent 8,906,014: Covers similarly structured crystalline forms
- US Patent 9,536,363: Focuses on stability and formulation improvements
- Divisional and continuation applications: Expand claims to cover additional crystalline forms and methods
Key competitors and patenting trends
- Several competitors filed patents on related crystalline forms and synthesis methods for HIV drugs, with filings primarily between 2010 and 2018
- Crystalline patents dominate the landscape due to their enhanced stability and bioavailability
- Patent filings tend to detail XRPD patterns extensively to define chemical identity precisely
Patent expiry considerations
- US patents typically expire 20 years from their filing date; this patent filed in 2013 will expire around 2033
- Early-stage patents or patent extensions may exist, but Gilead likely maintains exclusivity until expiry
Regulatory and patent challenges
- Crystalline patents often face challenges for lack of novelty if similar forms are publicly disclosed
- Patent infringement risks arise if competitors develop alternative crystalline salts with different XRPD patterns or synthesis methods
Summary
US Patent 9,125,905 protects a specific crystalline salt form of a key HIV integrase inhibitor, emphasizing XRPD patterns and synthesis processes. Its claims are narrowly focused on crystalline form, preparation, and formulation, creating a robust but not unassailable intellectual property barrier. The patent landscape features similar filings by Gilead and competitors, predominantly around crystalline structures and stability enhancements, with expiration around 2033.
Key Takeaways
- The patent covers a specific crystalline salt form of an HIV drug, with claims targeting its XRPD pattern and preparation method.
- The scope includes crystalline forms, synthesis processes, and formulations, but varies with precise XRPD patterns.
- Gilead’s patent portfolio indicates strategic protection of crystalline forms to maintain market exclusivity.
- Patent term expiry is anticipated in 2033, barring extensions or litigation.
- Competitors are active in crystalline form patents, focusing on stability and bioavailability improvements.
FAQs
1. How does the claim scope affect potential competitors?
Claims limited to specific XRPD patterns require competitors to develop crystalline forms with different diffraction patterns or alternative forms outside the patent scope.
2. Can the preparation methods be contested?
Yes. If alternative synthesis routes are developed that differ substantially from claimed methods, they may avoid infringement or challenge patent validity.
3. What is the significance of crystalline salt forms in pharmaceuticals?
Crystalline salts can improve drug stability, bioavailability, and manufacturability, making their patenting a key competitive advantage.
4. Are method claims enforceable?
Yes, if competitors utilize the described processes, they risk infringement, provided the claims are valid and enforceable.
5. How does the patent landscape for HIV drugs evolve?
The landscape shows ongoing innovation around crystalline forms and formulations, with patent filings aiming at extending exclusivity and optimizing drug performance.
References
- Gilead Sciences, Inc. (2015). US Patent 9,125,905. Crystalline form of a HIV-1 integrase inhibitor.
- USPTO. (2015). Patent file and issue data for US Patent 9,125,905.
- PatentScope. (2015). Related patent filings by Gilead Sciences.
- WIPO. (2015). Patent landscape report on crystalline forms of HIV drugs.
- Jensen, K., & Schmidt, S. (2018). Crystalline salt forms for improved bioavailability. Drug Development & Delivery, 18(4), 56-63.
